BMS and Tibotec partner for PhII HCV combo study
This article was originally published in Scrip
Executive Summary
The keen interest among firms to develop a potential interferon-free combination for the treatment of hepatitis C virus (HCV) has led to another partnership. Bristol-Myers Squibb and Tibotec Pharmaceuticals (J&J) have formed a deal to carry out a Phase II trial evaluating the combination of their respective investigational HCV oral candidates, declatasvir (BMS-790052) and TMC435. BMS’s declatasvir is claimed by the firm to a first-in-class NS3a replication complex inhibitor, while Tibotec’s TMC435 is a protease inhibitor which it is developing with Medivir. Both candidates are used in a once-daily regimen and are in Phase III.